Kaletra (Lopinavir/Ritonavir)
| Brand Name: |
Kaletra |
| Generic Name: |
Lopinavir/Ritonavir, LPV/RTV |
| Adult Single Dose*: |
400/100 mg (two 200/50-mg tablets or 5-mL oral solution) twice daily |
| Food & Liquid Restrictions: |
Oral solution must be taken with food. Tablets can be taken with or without food. Side effects may be lessened with food. |
| Drug Class: |
PI |
| * This recommendation is for patients starting HIV treatment. A different dose is recommended for treatment experienced patients. |
The Basics
- Lopinavir + Ritonavir (Kaletra) (November 30, 2012)
To read PDF, click here.
From AIDS InfoNet
- An Overview of Kaletra (Lopinavir/Ritonavir) (September 13, 2012)
From AIDSinfo
- Kaletra (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- FAQs About Kaletra (Lopinavir/Ritonavir) (January 12, 2012)
From The Body's "Ask the Experts" Forums
- Medication Guide for Kaletra (February 2011)
Created by the makers of Kaletra specifically for people with HIV. Includes a rundown of possible side effects, reasons why Kaletra may not be a good fit for everybody, meds to avoid while taking Kaletra, and tips on how to maximize the chances Kaletra will work well.
From Abbott Laboratories
- Patient Information About Kaletra (Lopinavir/Ritonavir) Tablets and Oral Solution (PDF) (February 2011)
From Abbott Laboratories
- Patient Frequently Asked Questions (2011)
Information about the new Kaletra (lopinavir/ritonavir) tablets.
From Abbott Laboratories
- Kaletra (Lopinavir/Ritonavir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Lopinavir (Kaletra) (August 15, 2006)
From AIDS Treatment Data Network
- Kaletra (Lopinavir/Ritonavir) (November 2005)
To read PDF, click here.
From The Center for AIDS
VIEW ALL ARTICLES
News
- Abbott Cuts Cost of AIDS Drug for Government Programs (May 10, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Abbott Cuts Cost of AIDS Drug for Government Programs (April 29, 2011)
In Chicago Tribune
- Lopinavir/r Oral Solution (March/April 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- U.S. Jury Rejects Glaxo Antitrust Claim vs. Abbott (March 31, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- U.S. Warns Against Abbott HIV Drug in Premature Babies (March 9, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Kaletra (Lopinavir/Ritonavir) Oral Solution Label Changes Related to Toxicity in Preterm Neonates (February 24, 2011)
From U.S. Food and Drug Administration
- Once a Day Kaletra Gets Approved for Treatment Experienced, but With Caution (February 2011)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Indian Government Rejects Abbott's Patent Application for Second-Line ARV (January 4, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Lopinavir/Ritonavir Approved (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- FDA Probes Risks of HIV, Prostate, Other Drugs (May 4, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
VIEW ALL ARTICLES
Research
- Lopinavir/Ritonavir Equivalent to Nevirapine in Ugandan Children (March 14, 2013)
From aidsmap.com
- HIV Drug Not Tied to Premature Births (March 8, 2013)
From MedPage Today
- Lopinavir/Ritonavir in Pregnancy: Results From a Systematic Review (January/February 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Simplified Protease Inhibitor Monotherapy Fails to Maintain HIV Suppression (October 26, 2012)
From HIVandHepatitis.com
- Simplifying HAART Regimen Fails to Maintain HIV-1 Viral Suppression (October 23, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- Novel Lopinavir/Ritonavir Sprinkle Formulation for Children in Resource-Limited Settings (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Lopinavir/Ritonavir Monotherapy in Children (March/April 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Lower Malaria Risk in Children Receiving Lopinavir/Ritonavir-Based Compared to NNRTI-Based ART (March/April 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- ARV Given to HIV-Positive Children Boosts Preventive Power of Key Malaria Drug, Study Shows (March 15, 2012)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- The Effect of BMI on Efficacy, Safety and Tolerability of Lopinavir/r in Women (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
